The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056

Growth Factors

Volumn 25, Issue 5, 2007, Pages 329-333

  Gallo, Richard M ^a   Riese II, David J ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

ErbB4; Phosphospecific antibody; Receptor tyrosine kinase; Tyrosine phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; PHOSPHOPEPTIDE; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY SC 33040 R; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FIBROBLAST; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PHOSPHO-SPECIFIC; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; HUMANS; MICE; PHOSPHORYLATION; RABBITS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYROSINE;

EID: 38849111769     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977190701804008     Document Type: Article

References (40)

1. Bangalore, L., Tanner, AJ, Laudano, AP and Stern, DF (1992) Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor. Proc Natl Acad Sci USA, 89:23, pp. 11637-11641.
2. DiGiovanna, MP (1997) Phosphorylation sensitivity of the commonly used anti-p185neu/erbB2 monoclonal antibody clone 3B5 suggests selective usage of autophosphorylation sites. Anal Biochem, 247:1, pp. 167-170.
3. DiGiovanna, MP and Stern, DF (1995) Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res, 55:9, pp. 1946-1955.
4. DiGiovanna, MP, Carter, D., Flynn, SD and Stern, DF (1996) Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer, 74:5, pp. 802-806.
5. Elenius, K., Choi, CJ, Paul, S., Santiestevan, E., Nishi, E. and Klagsbrun, M. (1999) Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene, 18:16, pp. 2607-2615.
6. Epstein, RJ, Druker, BJ, Roberts, TM and Stiles, CD (1992) Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci USA, 89:21, pp. 10435-10439.
7. Gallo, RM, Bryant, I., Fry, R., Williams, EE and Riese II, DJ (2006) Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Commun, 349:1, pp. 372-382.
8. Grasso, AW, Wen, D., Miller, CM, Rhim, JS, Pretlow, TG and Kung, HJ (1997) ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene, 15:22, pp. 2705-2716.
9. Hobbs, SS, Coffing, SL, Le, AT, Cameron, EM, Williams, EE, Andrew, M., Blommel, EN, Hammer, RP, Chang, H. and Riese II, DJ (2002) Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene, 21:55, pp. 8442-8452.
10. Hobbs, SS, Cameron, EM, Hammer, RP, Le, AT, Gallo, RM, Blommel, EN, Coffing, SL, Chang, H. and Riese II, DJ (2004) Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene, 23:4, pp. 883-893.
11. Jolivalt, CG, Jiang, Y., Freshwater, JD, Bartoszyk, GD and Calcutt, NA (2006) Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats. Diabetologia, 49:11, pp. 2775-2785.
12. Junttila, TT, Sundvall, M., Maatta, JA and Elenius, K. (2000) Erbb4 and its isoforms: Selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med, 10:7, pp. 304-310.
13. Junttila, TT, Sundvall, M., Lundin, M., Lundin, J., Tanner, M., Harkonen, P., Joensuu, H., Isola, J. and Elenius, K. (2005) Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res, 65:4, pp. 1384-1393.
14. Kew, TY, Bell, JA, Pinder, SE, Denley, H., Srinivasan, R., Gullick, WJ, Nicholson, RI, Blamey, RW and Ellis, IO (2000) c-erbB-4 protein expression in human breast cancer. Br J Cancer, 82:6, pp. 1163-1170.
15. Kumar, R. and Vadlamudi, RK (2000) The EGF family of growth factors. J Clin Ligand Assay, 23:3, pp. 233-238.
16. Lyne, JC, Melhem, MF, Finley, GG, Wen, D., Liu, N., Deng, DH and Salup, R. (1997) Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am, 3:1, pp. 21-30.
17. Maatta, JA, Sundvall, M., Junttila, TT, Peri, L., Laine, VJ, Isola, J., Egeblad, M. and Elenius, K. (2006) Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell, 17:1, pp. 67-79.
18. Mann, R., Mulligan, RC and Baltimore, D. (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell, 33:1, pp. 153-159.
19. Modi, S., DiGiovanna, MP, Lu, Z., Moskowitz, C., Panageas, KS, Van Poznak, C., Hudis, CA, Norton, L., Tan, L. and Stern, DF (2005) Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest, 23:6, pp. 483-487.
20. Mulloy, R., Ferrand, A., Kim, Y., Sordella, R., Bell, DW, Haber, DA, Anderson, KS and Settleman, J. (2007) Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res, 67:5, pp. 2325-2330.
21. Onguru, O., Scheithauer, BW, Kovacs, K., Vidal, S., Jin, L., Zhang, S., Ruebel, KH and Lloyd, RV (2004) Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol, 17:7, pp. 772-780.
22. Ouyang, X., Gulliford, T., Zhang, H., Huang, GC and Epstein, R. (1996) Human cancer cells exhibit protein kinase C-dependent c-erbB-2 transmodulation that correlates with phosphatase sensitivity and kinase activity. J Biol Chem, 271:36, pp. 21786-21792.
23. Ouyang, X., Gulliford, T., Doherty, A., Huang, GC and Epstein, RJ (1999) Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies. Lancet, 353:9164, pp. 1591-1592.
24. Ouyang, X., Gulliford, T., Huang, GC, Harper-Wynne, C., Shousha, S. and Epstein, RJ (2001) Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer. Mol Diagn, 6:1, pp. 17-25.
25. Penington, DJ, Bryant, I. and Riese II, DJ (2002) Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ, 13:6, pp. 247-256.
26. Pitfield, SE, Bryant, I., Penington, DJ, Park, G. and Riese II, DJ (2006) Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res, 16:4, pp. 179-193.
27. Riese II, DJ, van Raaij, TM, Plowman, GD, Andrews, GC and Stern, DF (1995) The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol, 15:10, pp. 5770-5776.
28. Riese II, DJ and DiMaio, D. (1995) An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene, 10:7, pp. 1431-1439.
29. Rittie, L., Kansra, S., Stoll, SW, Li, Y., Gudjonsson, JE, Shao, Y., Michael, LE, Fisher, GJ, Johnson, TM and Elder, JT (2007) Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin. Am J Pathol, 170:6, pp. 2089-2099.
30. Robinson, D., He, F., Pretlow, T. and Kung, HJ (1996) A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA, 93:12, pp. 5958-5962.
31. Suo, Z., Risberg, B., Kalsson, MG, Willman, K., Tierens, A., Skovlund, E. and Nesland, JM (2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol, 196:1, pp. 17-25.
32. Sweeney, C., Lai, C., Riese II, DJ, Diamonti, AJ, Cantley, LC and Carraway III, KL (2000) Ligand discrimination in signaling through an ErbB4 receptor homodimer. J Biol Chem, 275:26, pp. 19803-19807.
33. Thelemann, A., Petti, F., Griffin, G., Iwata, K., Hunt, T., Settinari, T., Fenyo, D., Gibson, N. and Haley, JD (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics, 4:4, pp. 356-376.
34. Thor, AD, Liu, S., Edgerton, S., Moore II, D., Kasowitz, KM, Benz, CC, Stern, DF and DiGiovanna, MP (2000) Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol, 18:18, pp. 3230-3239.
35. Tovey, SM, Witton, CJ, Bartlett, JM, Stanton, PD, Reeves, JR and Cooke, TG (2004) Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res, 6:3, pp. R246-R251.
36. Van Schaeybroeck, S., Karaiskou-McCaul, A., Kelly, D., Longley, D., Galligan, L., Van Cutsem, E. and Johnston, P. (2005) Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res, 11:20, pp. 7480-7489.
37. Williams, EE, Trout, LJ, Gallo, RM, Pitfield, SE, Bryant, I., Penington, DJ and Riese II, DJ (2003) A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett, 192:1, pp. 67-74.
38. Witton, CJ, Reeves, JR, Going, JJ, Cooke, TG and Bartlett, JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 200:3, pp. 290-297.
39. Yarden, Y. and Sliwkowski, MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2:2, pp. 127-137.
40. Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A. and Yoshinaga, SK (1996) Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem, 271:7, pp. 3884-3890.